A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M ™
Conditions: Malaria,Falciparum Interventions: Biological: R21/Matrix M ™ (Group 1); Biological: R21/Matrix M™ (Group 2); Biological: R21/Matrix M™ (Group 3); Procedure: Fine needle aspiration (FNA) Sponsors: University of Oxford; Bill and Melinda Gates Foundation; University Hospitals Bristol and Weston NHS Foundation Trust Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 20, 2024 Category: Research Source Type: clinical trials
A Study to Compare Two Dosing Regimens for a New Malaria Vaccine
Conditions: Malaria; Malaria,Falciparum; Protozoan Infections; Parasitic Disease; Infections; Vector Borne Diseases Interventions: Biological: Matrix M with RH5.1 Sponsors: University of Oxford Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 21, 2023 Category: Research Source Type: clinical trials
Assessment of Safety, Immunogenicity and Efficacy of R21/Matrix-M1 Malaria Vaccine in Healthy WOCBP in Mali
Conditions: Healthy Women of Child Bearing Potential Interventions: Biological: R21/Matrix-M1; Biological: Saline and R21/Matrix-M1; Other: Sterile isotonic (0.9%) normal saline Sponsors: European Vaccine Initiative; University of Oxford; Malaria Research and Training Center, Bamako, Mali Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 12, 2023 Category: Research Source Type: clinical trials
A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria
Conditions: Malaria Interventions: Biological: BNT165e; Other: Placebo Sponsors: BioNTech SE Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 6, 2023 Category: Research Source Type: clinical trials
Mass Vaccine and Drug Administration, Bangladesh
Conditions: Plasmodium Falciparum Malaria Interventions: Drug: DHA/piperaquine and a SLD-PQ; Biological: Study vaccine R21/Matrix-M ™ Sponsors: University of Oxford Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 5, 2023 Category: Research Source Type: clinical trials
R21/Matrix-M ™ Malaria Vaccine with Novavax’s Adjuvant Technology Receives WHO Recommendation
October 2, 2023 - Today, the World Health Organization (WHO) announced its recommendation of the R21/Matrix-M™ malaria vaccine to prevent malaria in children following advice from its Strategic Advisory Group of Experts (SAGE) and Malaria... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 2, 2023 Category: Pharmaceuticals Source Type: clinical trials
A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines
Conditions: Malaria; Malaria,Falciparum; Parasitic Disease; Vector Borne Diseases; Infections Intervention: Biological: RH5.1 and/or RH5.2-VLP with Matrix-M Sponsor: University of Oxford Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 7, 2023 Category: Research Source Type: clinical trials
COVID Transmission and Morbidity in Malawi
Conditions: SARS CoV 2 Infection; SARS CoV 2 Vaccination Intervention: Sponsors: Boston University; National Institute of Allergy and Infectious Diseases (NIAID); Malaria Alert Center, Kamuzu University of Health Sciences; Burnet Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 2, 2023 Category: Research Source Type: clinical trials
